ACADIA PHARMACEUTICALS INC (ACAD) is a publicly traded company in the Unknown sector. Across all available filings, 38 corporate insiders have executed 901 transactions totaling $781.4M, demonstrating a bullish sentiment with $513.6M in net insider flow. The most recent transaction on Feb 9, 2026 involved a sale of 6,950 shares valued at $162.5K.
No significant insider buying has been recorded for ACAD in the recent period.
No significant insider selling has been recorded for ACAD in the recent period.
Based on recent SEC filings, insider sentiment for ACAD is bullish with an Insider Alignment Score of 83/100 and a net flow of $513.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at ACADIA PHARMACEUTICALS INC (ACAD) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 38 insiders are actively trading ACAD stock, having executed 901 transactions in the past 90 days. The most active insider is L.p. 14159, (Executive), who has made 5 transactions totaling $200.0M.
Get notified when executives and directors at ACAD file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | J. Rhodes Jennifer | EVP, CHIEF LEGAL OFFICER, SEC | Sale | 6,950 | $23.38 | $162.5K | |
| Feb 6, 2026 | J. Rhodes Jennifer | EVP, CHIEF LEGAL OFFICER, SEC | Option Exercise | 12,944 | $N/A | $0 | |
| Feb 6, 2026 | J. Rhodes Jennifer | EVP, CHIEF LEGAL OFFICER, SEC | Option Exercise | 12,944 | $N/A | $0 | |
| Nov 18, 2025 | Kihara James | Executive | Sale | 4,084 | $23.69 | $96.7K | |
| Nov 18, 2025 | C. Schneyer Mark | Executive | Sale | 10,262 | $23.69 | $243.1K | |
| Nov 17, 2025 | Kihara James | Executive | Option Exercise | 3,966 | $N/A | $0 | |
| Nov 17, 2025 | Kihara James | Executive | Option Exercise | 3,966 | $N/A | $0 | |
| Nov 17, 2025 | C. Schneyer Mark | Executive | Option Exercise | 9,913 | $N/A | $0 | |
| Nov 17, 2025 | C. Schneyer Mark | Executive | Option Exercise | 9,913 | $N/A | $0 | |
| Nov 10, 2025 | M. Daly James | Executive | Sale | 30,000 | $22.37 | $671.1K | Large |
| Sep 15, 2025 | C. Schneyer Mark | Executive | Sale | 3,498 | $23.65 | $82.7K | |
| Sep 12, 2025 | C. Schneyer Mark | Executive | Award | 6,815 | $N/A | $0 | |
| Sep 2, 2025 | A. Garofalo Elizabeth | Executive | Sale | 1,600 | $25.98 | $41.6K | |
| Aug 18, 2025 | C. Schneyer Mark | Executive | Sale | 22,000 | $25.18 | $554.0K | Large |
| Aug 19, 2024 | Davis Stephen | Executive | Sale | 31,747 | $15.28 | $485.1K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 114 | $647.5M | 78.5% |
Sale(S) | 316 | $133.9M | 16.2% |
Exercise(M) | 361 | $41.5M | 5.0% |
Payment(F) | 2 | $2.0M | 0.2% |
Award(A) | 24 | $0 | 0.0% |
Gift(G) | 78 | $0 | 0.0% |
Other(J) | 6 | $0 | 0.0% |
Insiders at ACADIA PHARMACEUTICALS INC are accumulating shares at an accelerated pace. With 38 insiders making 901 transactions totaling $647.5M in purchases versus $133.9M in sales, the net buying activity of $513.6M signals strong executive confidence. L.p. 14159, (Executive) leads the buying activity with $200.0M in transactions across all time.